English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/220087
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

Title

Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins

AuthorsDíez, José María; Romero, Carolina; Vergara-Alert, Júlia; Bello Pérez, Melissa; Rodón, Jordi; Honrubia, José M. ; Segalés, Joaquim; Solá Gurpegui, Isabel ; Enjuanes Sánchez, Luis ; Gajardo, Rodrigo
KeywordsCOVID-19
Cross-neutralization
Intravenous immunoglobulin
MERS-CoV
SARS-CoV
SARS-CoV-2
Issue Date8-Sep-2020
PublisherFuture Medicine
CitationImmunotherapy (2020)
AbstractBackground: Cross-reactivity against human coronaviruses with Flebogamma® DIF and Gamunex®-C, two available intravenous immunoglobulins (IVIG), has been reported. In this study, these IVIG were tested for neutralization activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV). Materials & methods: Neutralization capacity of lots of IVIG manufactured prior to COVID-19 pandemic was assessed against these viruses in cell culture. Infectivity neutralization was quantified by percent reduction in plaque-forming units and/or cytopathic/cytotoxic methods. Results: All IVIG preparations showed neutralization of SARS-CoV-2 isolates. All IVIG lots produced neutralization of SARS-CoV. No IVIG preparation showed significant neutralizing activity against MERS-CoV. Conclusion: The tested IVIG contain antibodies with significant in vitro cross-neutralization capacity against SARS-CoV-2 and SARS-CoV, but not MERS-CoV. These preparations are currently under evaluation as potential therapies for COVID-19.
Publisher version (URL)https://doi.org/10.2217/imt-2020-0220
URIhttp://hdl.handle.net/10261/220087
DOI10.2217/imt-2020-0220
ISSN1750-743X
E-ISSN1750-7448
Appears in Collections:(CNB) Artículos
(VICYT) Colección Especial COVID-19
Files in This Item:
File Description SizeFormat 
Cross-neutralization activity against.pdf877,97 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.